Katabami Takuyuki, Murakami Mariko, Kobayashi Suzuko, Matsui Tomoya, Ujihara Makoto, Takagi Sachiko, Higa Mariko, Ichijo Takamasa, Ohta Akio, Tanaka Yasushi
Division of Metabolism and Endocrinology, Department of Internal Medicine, St Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, Japan.
J Int Med Res. 2014 Apr;42(2):457-67. doi: 10.1177/0300060513507648. Epub 2014 Mar 4.
To analyse the efficacy of low-dose rosuvastatin for treating hypo high-density lipoprotein (HDL) cholesterolaemia in patients with type 2 diabetes and dyslipidaemia.
Patients with HDL-cholesterol (C) < 40 mg/dl and triglycerides (TG) < 400 mg/dl who were receiving treatment with lipid-lowering drugs other than rosuvastatin (or previously untreated with lipid-lowering drugs) and with low-density lipoprotein [LDL]-C ≥ 120 mg/dl were included. Patients were treated with 2.5 or 5 mg rosuvastatin orally, once daily, to achieve the target LDL-C level specified in Japanese guidelines. Changes in total cholesterol, HDL-C, TG, LDL-C, LDL-C/HDL-C and non-HDL-C at 3 and 6 months were prospectively analysed. Safety was evaluated by examining changes in hepatorenal function, glucose metabolism and creatine kinase.
Out of 49 patients, all lipid parameters other than TG were significantly improved at 3 and 6 months. At 3 months, 83.3% of patients had achieved the target LDL-C level. Among nonlipid parameters, no changes were observed except for estimated glomerular filtration rate, which was improved by + 5.2% and + 9.6% at 3 and 6 months, respectively.
Low-dose rosuvastatin was effective in improving hypo-HDL cholesterolaemia and may have renoprotective effects.
分析小剂量瑞舒伐他汀治疗2型糖尿病合并血脂异常患者低高密度脂蛋白（HDL）胆固醇血症的疗效。
纳入高密度脂蛋白胆固醇（HDL-C）<40mg/dl且甘油三酯（TG）<400mg/dl，正在接受除瑞舒伐他汀以外的降脂药物治疗（或既往未接受过降脂药物治疗）且低密度脂蛋白[LDL]-C≥120mg/dl的患者。患者口服2.5或5mg瑞舒伐他汀，每日1次，以达到日本指南规定的目标LDL-C水平。前瞻性分析3个月和6个月时总胆固醇、HDL-C、TG、LDL-C、LDL-C/HDL-C和非HDL-C的变化。通过检查肝肾功能、糖代谢和肌酸激酶的变化来评估安全性。
49例患者中，除TG外的所有血脂参数在3个月和6个月时均有显著改善。3个月时，83.3%的患者达到了目标LDL-C水平。在非血脂参数中，除估计肾小球滤过率外未观察到变化，估计肾小球滤过率在3个月和6个月时分别提高了5.2%和9.6%。
小剂量瑞舒伐他汀可有效改善低HDL胆固醇血症，可能具有肾脏保护作用。
